Rebuyas, Mary Joy .
HRN: 19-25-43 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/25/2023
CO-AMOXICLAV 625MG (TAB)
08/25/2023
08/31/2023
ORAL
625mg
BID
UTI
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes